Biomarker panel for early detection in uterine cancer: a review

Abstract

Uterine cancer is the numerous prevalent cancers of the female reproductive tract inindustrialized as well as developing countries and its probability is arising annually.There is a total of approximated 90,000 mortality and 382,000 instances newly cas-es treated annually globally. The desire to create and define biological markers forthe initial stages detection and therapy of uterine cancer is growing. We analyze thecurrent state of biomarker utilization for early detection, including their sensitivityand specificity, paving the way for timely interventions. Several biomarkers, includ-ing P53, K-RAS, CA-125, HER2/neu, HE4, PTEN, MSI are used for early detection,treatment, and prevention of uterine cancer. Prognostic biomarkers in uterine cancerhave emerged as indispensable tools for predicting disease progression and patientoutcomes. Endometrial biopsy, CT scan, MRI Scan, Dilation and Curettage, Trans-vaginal ultrasound are vital for diagnosing and staging of uterine cancer and provideessential information about the cancer’s presence, size, and spread, guiding propertreatment decisions. Various treatments modalities, including surgery, Chemother-apy, targeted therapies are examined. In conclusion, early detection through bio-markers like P53, K-RAS, HER2/neu, PTEN, Serum CA-125 holds great promise forearly diagnosis and treatment advancements, as well as providing hope for betterresults and a higher standard of living for individuals in future generations.